BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAYTUS Launches MotusAI Enterprise Token Management Platform4.6.2026 09:02:00 CEST | Press release
KAYTUS, a leading provider of AI infrastructure and liquid cooling solutions, today announced the launch of enterprise-grade token management capabilities within MotusAI, enabling organizations to rapidly build, deploy, and operate secure on-premises AI token platform. This pioneering infrastructure enhancement transforms traditional GPU hardware into a unified, governable, and highly efficient internal token service ecosystem. By enabling rapid private deployment, MotusAI provides enterprises with a cost-competitive foundation for accelerating the scale-up of enterprise-grade AI agents while ensuring strong data privacy. Why Enterprises Must Build a Private Token Management Platform Now? As enterprise AI evolves from isolated model-based tools to interconnected AI agent systems that enable deep workflow automation, tokens are emerging as the fundamental “computing currency” of the modern organization. While standard LLM queries typically involve predictable, one-off inference requests
FPT Achieves AWS Manufacturing and Industrial Competency and AWS Automotive Competency4.6.2026 09:00:00 CEST | Press release
FPT, a globally leading technology and IT services provider, announced today that it has achieved the Amazon Web Services (AWS) Manufacturing and Industrial Competency and the Automotive Services Competency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604861727/en/ FPT Achieves AWS Manufacturing and Industrial Competency and AWS Automotive Competency AWS enables scalable, flexible, and cost-effective solutions from startups to global enterprises. To support the seamless integration and deployment of these solutions, the AWS Competency Program helps customers identify AWS Partners with deep industry experience and expertise. These designations recognize FPT’s proven expertise in delivering cloud services and industry solutions that help manufacturing and automotive enterprises modernize operations, accelerate software-led innovation, and advance digital transformation on AWS. Meeting Manufacturers and Automakers Where
Network X 2026 Opens New Chapter in Vienna with Expanded European Focus and Telecom Industry Leaders4.6.2026 08:00:00 CEST | Press release
Drei Austria CEO Rudolf Schrefl and RTR’s Dr. Klaus Steinmaurer Among First Confirmed Keynotes for 2026 Debut Network X today unveiled the first details of its 2026 edition, marking a major evolution for the international telecoms event as it relocates to Vienna for the first time. Taking place 13-15 October at VIECON, the event will bring together more than 5,500 telecom leaders, operators, infrastructure providers, hyperscalers, policymakers and technology innovators from across Europe and beyond. Registration is now open. The move to Vienna reflects the growing strategic importance of Central and Eastern Europe in the future of digital infrastructure investment, fibre expansion, data centre networks, AI-enabled mobile networks and next-generation communication services. Austria’s accelerating broadband ambitions and position between Western and Eastern European markets make Vienna a natural fit for the next phase of Network X. Among the first keynote speakers announced for 2026 are
Notice of Multi-Color First Quarter 2026 Financial Results Conference Call4.6.2026 05:56:00 CEST | Press release
Multi-Color Corporation (“MCC”) First Quarter 2026 Financial Results Conference Call covering MCC’s performance for the quarter ending March 31, 2026. When: Monday, June 8th at 10:00 A.M. EDT Leaders: Hassan Rmaile, President & CEO and Kathleen Phelps, CFO Access: Existing and prospective investors can gain access to the investor data site (“Data Site”) by following the instructions section 2 below. If you previously had access to the investor data site then no action is needed as your access remains in place. Please submit access requests to the email address listed below in section 2 by 5pm ET Friday, June 5th. The live link to the first quarter 2026 financial results call will be posted to the investor data site. Investor Data Site Access Instructions: 1. Data site access Common Unit, Preferred Unit and Warrant holders of Labels Buyer, LLC (“Company”), holders of notes issued by Multi-Color Corporation and MCC Manufacturing, Inc. (collectively, the “Issuers”) and prospective investo
Kyrgyzstan’s National Interbank Processing Center Partners With Alipay+ to Launch International QR Payments4.6.2026 04:00:00 CEST | Press release
With the support of the National Bank of Kyrgyz Republic, Interbank Processing Center (IPC), Kyrgyzstan’s national payment system operator, and Alipay+, Ant International’s unified wallet gateway, have launched international QR payments for users of the ELCARD Mobile app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603760762/en/ (L-R) Altymysh Turatbekov, Chairman of the National Interbank Processing Center; Pan Yan, Head of Strategic Partnership for Alipay+, Ant International The launch was officiated by the Chairman of the National Bank of the Kyrgyz Republic. Almaz Baketaev, Chairman of the National Bank of the Kyrgyz Republic, said: “Our colleagues from IPC together with Alipay+ launched this project last year, and today we are bringing it into practice. Our citizens now have access to a payment system covering merchants worldwide. Wherever they are, they can make payments in any currency easily and without any com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom